Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer

References

• Fedi P, Pierce JH, Di Fiore PP et al Efficient coupling with phosphatidylinositol Cy or GTPase- activating protein distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mel Cell Biol. 14, 492–500 (1994).
   Google Scholar
• Earp HS, Dawson TL, Li X et a/. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res. Treat.35 (1), 115–132 (1995).
   Google Scholar
• Salomon DS, Brand R, Ciardiello F et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Grit. Rev Once]. I-kmatol 19, 183–232 (1995).
   PubMed Web of Science ®Google Scholar
• Walker R. The ErbB/HER Type 1 tyrosine kinase receptor family. I Pathol 185, 234–235 (1998).
   Google Scholar
• Prigent SA, Lemoine NR. The Type 1 (EGFR-related) family of growth factor receptors and their ligands. Pmg. Growth Factor Res. 4,1-24 (1992).
   Google Scholar
• Yokota J, Yamamoto T, Toyoshima K et al Amplifications of C-ErbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1, 765–767 (1986).
   PubMed Web of Science ®Google Scholar
• Lemoine NR, Barnes DM, Hollywood DP et al. Expression of the ErbB3 gene product in breast cancer. BE J. Cancer 66 116–1121 (1992).
   Google Scholar
• Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. BE Med. Bull. 47,87–98 (1991).
   PubMed Web of Science ®Google Scholar
• Ezeh P, Farbman A. Differential activation of ErbB receptors in the rat olfactory mucosa by transforming growth factor-CL and epidermal growth factor in vivo. J. Neurobial 37,199–210 (1998).
   Google Scholar
• Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Ann. Rev Biochem 57, 443–478 (1998).
   Google Scholar
• Brandt R, Eisenbrandt R, Leenders F et al. Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation. Oncogene 19, 2129–2137 (2000).
   Google Scholar
• Ennis BW, Lippman ME, Dickson RB. The EGF receptor system as a target for antitumor therapy. Cancer Invest 9, 553–562 (1991).
   Google Scholar
• Yao M, Shuin T, Misaki H et al Enhanced expression of c-myc and epidermal growth factor receptor (C-ErbB-1) genes in primary human renal cancer. Cancer Res. 48,6753-6757 (1998). Analyzing 12 proto-oncogenes in human renal cell carcinoma and adjacent normal kidneys by comparative densitometry of northern blot suggested that activation of c-MYCand c-ERB-1 genes may be involved in the development of human renal cell carcinomas.
   Google Scholar
• Harris AL, Nicholson S, Sainsbury JR et al Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. J. Steroid Biochem. 34,123–131 (1989).
   PubMedGoogle Scholar
• Fox SB, Smith K, Hollyer J et al. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res. Peat. 29,41-49 (1994).
   Google Scholar
• Lamerz R. Role of tumor markers, cytogenetics. Ann. Oncol 10,145–149 (1999).
   PubMed Web of Science ®Google Scholar
• Sainsbury JR, Famdon JR, Needham GK et al Epidermal growth factor receptor status as predictor of early recurrence and death from breast cancer. Lancet 1, 1398–1402 (1987).
   PubMed Web of Science ®Google Scholar
• Klijn JG, Look MP, Portengen H et al The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res. Peat. 29,73-83 (1994).
   Google Scholar
• Ohsaki Y, Tanno S, Fujita Y et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oiled Rep. 7,603–607 (2000).
   Google Scholar
• Hurtt MR, Mossy J, Donovan-Peluso M et al Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. Neuropathol Exp. Neural 51,84–90 (1992).
   PubMed Web of Science ®Google Scholar
• Veale D, Ashcroft T, Marsh C et al. Epidermal growth factor receptors in non-small cell lung cancer. BE J. Cancer 55, 513–516 (1987).
   Google Scholar
• Yamanaka Y. The immunohistochemical expressions of epidermal growth factors, epidermal growth factor receptors and c-ErbB-2 oncoprotein in human pancreatic cancer. 1Nippon. Med. Sch. 59,51-61 (1992).
   Google Scholar
• Dong M, Nio Y, Guo KJ et al Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res. 18, 4613–4619 (1998).
   PubMed Web of Science ®Google Scholar
• Krupski T, Moskaluk C, Boyd JC et al A prospective pilot evaluation of urinary and immunohistochemical markers as predictors of clinical stage of urothelial carcinoma of the bladder. BJU/nt. 85, 1027–1032 (2000).
   Google Scholar
• Nguyen PL, Swanson PE, Jaszcz W et al Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder: a multivariate survival analysis. Am. J. Clin. Pathol 101,166–176 (1994).
   PubMed Web of Science ®Google Scholar
• Bartlett JMS, Langdon SP, Simpson BJB et al The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. BE I Cancer 73, 301–306 (1996).
   Google Scholar
• Kristensen GB, Holm R, Abeler VM et al Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor and c-ErbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Cancer 78, 433–434 (1996).
   Google Scholar
• Iihara K, Shiozaki H, Tahara H et al Prognostic significance of transforming growth factor-CL in human esophageal carcinoma. Implication for the autocrine proliferation. Cancer 71,2902–2909 (1993).
   Google Scholar
• Shin DM, Donato NJ, Perez-Soler R et al Epidermal growth factor receptor-targeted therapy with humanized chimeric monoclonal antibody, C225, in combination with cisplatin in patients with head and neck cancer. Clin. Cancer Res. 7(5), 1204–1213 (2001).
   Google Scholar
• Grandis JR, Melhem ME, Barnes EL et al Quantitative immunohistochemical analysis of transforming growth factor-CL and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78,1284–1292 (1996).
   PubMed Web of Science ®Google Scholar
• Shin DM, Ro JY, Hong WK et al Dysregulation of epidermal growth factor receptor expression in multistep process of head and neck tumorigenesis. Cancer Res. 54,3153–3159 (1994).
   PubMed Web of Science ®Google Scholar
• •Specimens from 36 head and neck squamous cell carcinomas (HNSCC) were studied to identify a potential biomarker of the tumorigenesis process. Epidermal growth factor receptor (EGFR) expression remained elevated as tissue progressed from normal to hyperplasia to dysplasia, which may indicate that EGFR dysregulation might be a useful marker for identifying individuals at risk of tumor development.
   Google Scholar
• Klijn JG, Berns PMJ, Schmitz PIM et al The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 13,3–17 (1992).
   PubMed Web of Science ®Google Scholar
• Walker RA, Dearing SJ. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res. Treat. 53,167–176 (1999).
   PubMed Web of Science ®Google Scholar
• Bucci B, D'Agnano I, Botti C et al EGFR expression in ductal breast cancer: proliferation and prognostic implications. Anticancer Res. 17, 769–774 (1997).
   PubMed Web of Science ®Google Scholar
• VCAM M, Rittgen W, Drings P. Prognostic value of ErbB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. BE J. Cancer 77, 663–669 (1998).
   Google Scholar
• Pavelic K, Banjac Z, Pavelic J et al Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res. 13, 1133–1137 (1993).
   PubMed Web of Science ®Google Scholar
• Fujino S, Enokibori T, Tezuka N et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur. Cancer32A, 2070–2074 (1996).
   PubMed Web of Science ®Google Scholar
• Rusch V, Klimstra D, Venkatraman E et al Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor-CL is frequent in resectable non-small cell lung cancer but does not predict tumor progressions. Clin. Cancer Res. 3, 515–522 (1997).
   PubMed Web of Science ®Google Scholar
• ••Focused on the association betweenoverexpression of EGFR and transforming growth factor (TGF)-a and the overall survival of patients with resectable small cell lung cancer. EGFR and TGF-a overexpression is frequent in early-stage non-small cell lung cancer (NCSLC) but is not associated with a survival difference, which makes EGFR more important in lung tumor formation than for tumor progression.
   Google Scholar
• Fontanini G, De Laurentiis M, Vignati S et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected Stage non-small cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin. Cancer Res. 4, 241–249 (1998).
   PubMed Web of Science ®Google Scholar
• •Determined the expression of TGF-a, arnphiregulin, CRIPTO, EGFR, ERbB-3 and tumor angiogenesis in a series of patients with Stage I—IIIA NSCLC treated with radical surgery The result suggested that evaluation of neoangiogenesis and amphiregulin overexpression = 0.02) are useful in addition to pathological staging to select high-risk NSCLC patients who may benefit from postsurgical systemic therapies.
   Google Scholar
• Brabender J, Danenberg K, Metzger R et al Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin. Cancer Res. 7, 1850–1855 (2001).
   Google Scholar
• Messa C, Russo F, Caruso MG et al EGF, TGF-a and EGFR in human colorectal adenocarcinoma. Acta. °rico]. 37, 285–289 (1998).
   Google Scholar
• Mayer A, Takimoto M, Fritz E et al The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor and MDRgene expression in colorectal cancer. Cancer 71, 2454–2460 (1993).
   PubMed Web of Science ®Google Scholar
• Fischer-Colbrie J, Witt A, Heinzl H et al EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res. 17, 613–623 (1997).
   PubMed Web of Science ®Google Scholar
• Niikura H, Sasano H, Sato S et al Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors. Int. .1. Cynecol Pathol 16, 60–68 (1997).
   Google Scholar
• Chow NH, Liu HS, Lee El et al Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res. 17, 1293–1296 (1997).
   PubMed Web of Science ®Google Scholar
• Turkeri LN, Erton ML, Cevik I et al. Impact of the expression of epidermal growth factor, transforming growth factor-CL and epidermal growth factor receptor on the prognosis of superficial bladder cancer. Urology51, 645–649 (1998).
   PubMedGoogle Scholar
• Koullias GJ, Kouraklis GP, Raftopoulos IS et al Increased estrogen receptor and epidermal growth factor receptor gene product co-expression in surgically resected gastric adenocarcinomas. I Sorg. Oncol 63, 166–171 (1996).
   Google Scholar
• Ekstrand AJ, James CD, Cavanee WK et al Genes for epidermal growth factor receptor, transforming growth factor-CL and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51, 2164–2172 (1991).
   PubMed Web of Science ®Google Scholar
• ••Demonstrated that EGFR gene amplification was detected in 50% of the studied samples of Grade 4 gliomas and only in one of 30 gliomas of lesser malignancy grade.
   Google Scholar
• Solorzano C, Baker C, Tsan R et al Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin. Cancer Res. 7, 2563–2572 (2001).
   PubMed Web of Science ®Google Scholar
• ••Confirmed the blockade of the EGFR signaling pathway by oral administration of EGFR tyrosine kinase inhibitor PKI-166 combined with intraperitoneal injection of gemcitabine for therapy of pancreatic carcinoma growing in pancreatic nude mice. PKI-166 inhibits the intracellular domain of EGFR tyrosine kinase with an IC50 value of 0.7 nrn.
   Google Scholar
• Moyer JD, Barbacci EG, Iwata KK et al Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57, 4838–4848 (1997).
   PubMed Web of Science ®Google Scholar
• •Demonstrated selective inhibition of EGFR tyrosine kinase by preventing autophosphorylation of EGFR in xenograft mice by administering CP-358,774. This inhibition also triggers apoptosis in DiFi human colon tumor cell in culture and blocks cell cycle in G1 phase.
   Google Scholar
• Chu CT, Everiss KD, Wikstrand CJ et al Receptor dimerization is not a factor in the signaling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem.j 324, 855–861 (1997).
   PubMed Web of Science ®Google Scholar
• Stir= G, Eberwein S, Rostock-Wold S et al Concomitant overexpression of the EGFR and ErbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis. Int. J. Cancer69, 17–22 (1996).
   Google Scholar
• Wikstrand CJ, Hale LP, Batra SK et al Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55, 3140–3148 (1995).
   PubMed Web of Science ®Google Scholar
• •Five specific monoclonal antibodies (mAbs) have identified the EGFRvIII on the cell surface of lung carcinomas and malignant glioma as determined by radioimmunoassay, ELISA, western blot, analytic flow cytometry, autophosphorylation and imrnunohistochemistry.
   Google Scholar
• Chu CT, Everiss KD, Wikstrand CJ et al Receptor dimerization is not a factor in the signaling activity of a transforming variant epidermal growth factor (EGFRvIII). Biochem.j 324, 855–861 (1997).
   PubMed Web of Science ®Google Scholar
• Olapade-Olaopa EO, Moscatello DK, MacKay EH et al Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br.Cancer 82, 186–194 (2000).
   Google Scholar
• Wikstrand CJ, McLendon RE, Friedman AH et al Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 57,4130–4140 (1997).
   PubMed Web of Science ®Google Scholar
• Grandis JR, Melhem MF, Gooding WE et al Levels of TGF-a and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl Cancer Inst. 90, 824–832 (1998).
   PubMed Web of Science ®Google Scholar
• Prewett M, Rockwell RF, Rockwell P et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J. Immunother. 19,419-427 (1996).
   Google Scholar
• Baselga J, Mendelsohn J. Receptor blockade with monoclonal antibodies as anticancer therapy. Pharmacol Ther. 64,127–154 (1994).
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Antibodies to growth factors and receptors. Biol. Ther Cancer 607–623 (1995).
   Google Scholar
• Modjtahedi H, Dean C. The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer. int. J. Oncol 4,277–296 (1994).
   PubMed Web of Science ®Google Scholar
• Modjtahedi H, Styles JM, Dean CJ. The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468. Br. Cancer67, 247–253 (1993).
   Google Scholar
• Modjtahedi H, Eccles S, Box G et al Immunotherapy of human tumor xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. BEI Cancer67, 254–261 (1993).
   Google Scholar
• Sato JD, Kawamoto T, Le AD et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mot. Biol. Merl 1, 511–529 (1983).
   Google Scholar
• Fan Z, Mendelsohn J, Masui H et al Regulation of epidermal growth factor receptor in NIH3T3/1-1ER14 cells by antireceptor monoclonal antibodies. Chem. 268,21073–21079 (1993).
   Google Scholar
• Fan Z, Lu Y, Wu X et al Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J. Biol. Chem. 269, 27595–27602 (1994).
   Google Scholar
• Goldstein NI, Prewett M, Zuldys K et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1,1311–1318 (1995).
   PubMed Web of Science ®Google Scholar
• Chou J-L, Fan Z, DeBlasio T et al Constitutive overexpression of cyclin D1 in human breast epithelial cells does not prevent G1 arrest induced by deprivation of epidermal growth factor. Breast Cancer Res. Brat. 55,267-283 (1999).
   Google Scholar
• Markowitz SD, Molkentin K, Gerbic C et al Growth stimulation by coexpression of transforming growth factor-CL and epidermal growth factor receptor in normal and adenomatous human colon epithelium. Clin. Investig. 86,365–362 (1990).
   Google Scholar
• Perrotte P, Matsumoto T, Inoue K et al Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 5,257-265 (1999).
   Google Scholar
• ••Indicated that therapy with antiEGFRmAb C225 has a significant antitumor effect by inhibiting angiogenesis, which was evaluated by immunohistochemistry and microvessel density
   Google Scholar
• Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59,1935-1940 (1999).
   Google Scholar
• •Revealed that C225 enhances radiosensitivity and amplification of radiation-induced apoptosis in HNSCC.
   Google Scholar
• Mandal M, Adam L, Mendelsohn J et al Nuclear targeting of BAXduring epidermal growth factor receptor-induced apoptosis in colorectal cancer cells. Oncogene 17, 999–1007 (1998).
   PubMed Web of Science ®Google Scholar
• Petit AM, Rak J, Hung MC et al Neutralizing antibodies against epidermal growth factor and ERB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitm and in viva angiogenic implications for signal transduction therapy of solid tumors. Am J. Farhat. 151, 1523–1530 (1997).
   Google Scholar
• Bruns CJ, Harbison MT, Davis DW et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by anti-angiogenic mechanisms. Clin. Cancer Res. 6,1936-1948 (2000).
   Google Scholar
• Naramura M, Gillies SD, Mendelsohn J et al Therapeutic potential of chimeric and murine anti-epidermal growth factor receptor antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother. 37,343–349 (1993).
   PubMed Web of Science ®Google Scholar
• Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy - the fourth annual Joseph H Burchenal American association for Cancer Research, clinical research award lecture. Clin. Cancer Res. 6,747–753 (2000).
   PubMed Web of Science ®Google Scholar
• Fan Z, Masui H, Atlas I et al Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 53, 4322–4328 (1993).
   PubMed Web of Science ®Google Scholar
• ••Explored the mechanism by whichantiEGFR 225 mAb inhibits cell proliferation by comparing the activity of native 225 mAb with the response to bivalent 225Fab2 and monovalent 225Fab fragments.
   Google Scholar
• Baselga J, Norton L, Masui H et al Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl Cancer Inst. 85,1327–1333 (1993).
   PubMed Web of Science ®Google Scholar
• Fan Z, Baselga J, Masui H et al Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 53,4637–4642 (1993).
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Bianco R, Damiano V et al Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res. 5,909-916 (1999).
   Google Scholar
• •Evaluated the combination of mAb C225 with topotecan in human ovarian, breast and colon cancer cell lines, which expressed functional EGFR This combination markedly enhanced apoptotic cell death and provided the rationale of this combination of anticancer therapy in clinical trial.
   Google Scholar
• Baselga J, Pfister D, Cooper MR et al Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. Clin. Oiled 18,904–914 (2000).
   Google Scholar
• Gunnett K, Motzer R, Amato R et al Phase II study of anti-epidermal growth factor receptor (EGFR) antibody C225 alone in patients with metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol 389 (1999) (Abstract 19).
   Google Scholar
• Huag SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics and tumor angiogenesis. Clin. Cancer Res. 6,2166–2174 (2000).
   Google Scholar
• •Suggests that the profound in vivo antitumor activity identified in the xenograft setting when C225 is combined with radiation derives from more than simply the antiproliferative and cell cycle affects of EGFR system inhibition. In addition to antiproliferative growth inhibition, EGFR blockade with C225 appears to influence the capacity of human squamous cell carcinoma to effect DNA repair after exposure to radiation and to express classic markers of tumor angiogenesis.
   Google Scholar
• Ezekiel MP, Bonner JA, Robert E Phase I trial of chimerized epidermal growth factor receptor (EGFR) antibody in combination with once-daily or twice-daily irradiation for locally advanced head and neck malignancies. Proc. Am. Soc. Clin. Oncol (1999) (Abstract 1501).
   Google Scholar
• Baselga J. Monoclonal antibodies directed at growth factor receptors. Ann. Oncol 11 (Suppl. 13), 187–190 (2000).
   Google Scholar
• Perez-Soler R, Donato N, Shin D et al Tumor epidermal growth factor receptor studies in patients with non-small cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852. Clin. Oncol 12,730–739 (1994).
   Google Scholar
• ••Demonstrated that no significant sideeffects were observed using escalating doses of monoclonal antibody RG-83852 by intravenous infusion in patients with NSCLC or head and neck cancer. High degree of EGFR saturation (>50%) was observed at doses greater than 200 mg/m2 and EGFR saturation was estimated to be 100% at dose level of 600 mg/m2.
   Google Scholar
• Baselga J, Pfister D, Cooper MR et al Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. Clin. Oncol 18,904–914 (2000).
   Google Scholar
• •Evaluated the pharrnacokinetics and toxicity of C225 in patients with advanced tumor overexpression of EGFR C225 has dose-dependant pharmacokinetics and doses that achieve saturation of systemic clearance are well tolerated. C225 given in combination with cisplatin has biologic activity at pharmacologically relevant doses. C225-associated toxicity was also minimal.
   Google Scholar
• Crombet-Ramos T, Torres L, Salano M. Pharmacological and clinical evaluation of the humanized antiEGFR monoclonal antibody h-R3 in patients with advanced epithelial carcinomas. Proc. Am. Soc. Clin. Oncol (2001) (Abstract 1012).
   Google Scholar
• Yang XD, Jia XC, Corvalan J et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59, 1236–1243 (1999).
   PubMed Web of Science ®Google Scholar
• ••Revealed the ability of a fully humanmonoclonal antibody to completely eradicate A431 xenografts in treated mice for more than 8 months.
   Google Scholar
• Figlin RA, Belldegrun A, Lohner ME. ABX-EGF: a fully humanized antiEGF receptor antibody in patients with advanced cancer. Proc. Arn. Soc. Clin. Oncol (2001) (Abstract 1102).
   Google Scholar
• Modjtahedi H, Hickish T, Nicolson M et al. Phase I trial and tumor localization of the antiEGFR monoclonal antibody ICR62 in head and neck or lung cancer. BE Cancer73, 228–235 (1996).
   Google Scholar
• Hoffman T, Hafner D, Ballo H et al Antitumor activity of antiepidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Anticancer Res. 17,4419–4426 (1997).
   Google Scholar
• Stragliotto G, Vega F, Stasiecki P et al Multiple infusions of antiepidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55900) in patients with recurrent malignant gliomas. Eur. I Cancer 32A, 636–640 (1996).
   Google Scholar
• Sartor C. Biological modifiers as potential radiosensitizers: targeting the epidermal growth factor receptor family. Semin. Oncol (In Press).
   Google Scholar
• Mendelsohn J, Fan Z. Epidermal growth factor receptor family and chemosensitization. I Natl Cancer Inst. 89, 341–343 (1997).
   PubMed Web of Science ®Google Scholar
• Radke K, Gilmore T, Martin GS. Transformation by Rous sarcoma virus: a cellular substrate for transformation specific protein phosphorylation contains phosphotyrosine. Ce1121, 821–828 (1980).
   Google Scholar
• Macias A, Azavedo E, Hagerstrom T et al Prognostic significance of the receptor for epidermal growth factor receptor in human mammary cancers. Anticancer Res. 7, 459–64 (1987).
   PubMed Web of Science ®Google Scholar
• Akiyama T, Saito T, Ogawara H et al Tumor promoter and epidermal growth factor stimulate phosphorylation of the c-ErbB-2 gene product in MKN-7 human adenocarcinoma cells. Mal Cell Biol. 8, 1019–1926 (1988).
   Google Scholar
• Fava R, Cohen S. Isolation of a calcium- dependent 35-kDa substrate for the epidermal growth factor receptor/kinase from A-431 cells. Bid Chem. 259, 2636–2645 (1984). loo Haigler HT, Schlaepfer DD, Burgess WH. Characterization of lipocortin I and an immunologically unrelated 33-kDa protein as epidermal growth factor receptor/kinase substrate and phospholipase A2 inhibitors. I Rio. Chem. 262,6921-6930 (1987).
   Google Scholar
• Fry DW, Kraker AJ, McMichael A et al A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265, 1093–1095 (1994).
   PubMed Web of Science ®Google Scholar
• Karnes WE, Weller SG, Adjei PN et al Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells. Gastroenterology114, 930–939 (1998).
   PubMed Web of Science ®Google Scholar
• He Y, Zeng Q, Drenning SD et al Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. I Natl Cancer Inst. 90,1080–1087 (1998).
   PubMed Web of Science ®Google Scholar
• Fry DW. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Phatmacol Ther 82,207–218 (1999).
   Google Scholar
• Zaman GJ, Vink PM, Van den Doelen AA et al Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor 0-receptor (0-PDGFR) and discovery of a novel inhibition of receptor tyrosine kinases. Biochem. Pharmacol 57,57–64 (1999)
   Google Scholar
• Smaill JB, Palmer BD, Rewcastle GW et al Tyrosine kinase inhibitors: 15,4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibition of the ATP binding site of the epidermal growth factor receptor. I Merl Chem. 42, 1803–1815 (1999).
   PubMed Web of Science ®Google Scholar
• Showalter HD, Bridger AJ, Zhou H et al Tyrosine kinase inhibitors 16,6,5,6-tricyclic benzothieno3,2-dpyrimidines and pyrimido5,4-b- and -4,5- bindoles as potent inhibitions of epidermal growth factor receptor tyrosine kinase. j Merl Chem. 42, 5464–5474 (1999).
   PubMed Web of Science ®Google Scholar
• Noonberg SB, Benz CC. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs 59, 753–767 (2000).
   PubMed Web of Science ®Google Scholar
• Ghosh S, Zheng Y, Jun X et al a-cyano-3-hydroxy-3-methy-N14-(trifluoromethoxy)phenyl] propenamide: an inhibitor of the epidermal growth factor receptor tyrosine kinase with potent cytotoxic activity against breast cancer cells. Clin. Cancer Res. 4, 2657–2668 (1998).
   Google Scholar
• Sudbeck EA, Liu XP, Narla RK et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin. Cancer Res. 5, 1569–1582 (1999).
   Google Scholar
• ••Explored several structural-based designs ofdimethoxyquinazoline compounds which caused potent and specific inhibitory activity against JAK3-expressing human leukemia cell lines. These specific inhibitors provided the basis for the design of new treatment strategies against acute lymphoblastic leukemia. in Lane HA, Beuvink I, Motoyama AB et al. ERB-B2 potentiates breast tumor proliferation through modulation of p27 (KIP1)-CDK2 complex formation: receptor overexpression does not determine growth dependency. Mal Cell Biol. 20, 3210–3223 (2000).
   Google Scholar
• Woodburn JR, Barker AJ, Gibson KH et al ZD-1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development. Pmc. Am. Assoc. Cancer Res. (1997) (Abstract 4251).
   Google Scholar
• Sirotnak F, Zakowski M, Liller V et al Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (IRESSA), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6, 4885–4892 (2000).
   Google Scholar
• Woodburn JR, Kendrew J, Fennell M et al ZD-1839 (IRESSA), a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): inhibition of c-FOS mRNA, an intermediate marker of EGFR activation, correlates with tumor growth inhibition. Proc. Am Assoc. Cancer Res. (2000) (Abstract 2552).
   Google Scholar
• Cardiello F, Caputo R, Bianco R et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (IRESSA), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6, 2053–2063 (2000).
   Google Scholar
• •The antiproliferative activity of gefinitib alone or in combination with cytotoxic drugs was evaluated in human ovarian, breast and colon cancer cells that coexpress EGFR and TGF-a. A dose-dependent supra-additive increase in growth inhibition was observed when cancer cells were treated with each cytotoxic drug and gefinitib, demonstrating the antitumor effect of this EGFR-selective tyrosine kinase inhibitor.
   Google Scholar
• Ciardiello F, Damiano V, Bianco R et al Inhibition of EGFR-tyrosine kinase by ZD1839 (IRESSA) leads to antiproliferative and anti-angiogenic effects in human GEO colon cancer xenografts in combination with paclitaxel. Proc. Am. Assoc. Cancer Res. (2001) (Abstract 4580).
   Google Scholar
• Normanno N, Campiglio M, De Luca A et al Co-operative inhibitory effect of ZD1839 (IRESSA) in combination with trastuzumab on human breast cancer cell growth. Proc. Am. Assoc. Cancer Res. (2001) (Abstract 4156).
   Google Scholar
• Baselga J, Herbst R, LoRusso P et al Continuous administration of ZD-1839 (IRESSA), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected tumor types: evidence of activity and good tolerability. Proc. Am Sx. Clin. Oncol. (2000) (Abstract 686).
   Google Scholar
• Negoro S, Nakagawa K, Fukuoka M et al Final results of a Phase I intermittent dose-escalation trial of ZD 1839 (IRESSA®) in Japanese patients with various solid tumors. Proc. Am Soc. Clin. Oncol (2001) (Abstract 1292).
   Google Scholar
• Noonberg S, Benz C. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily. Drugs 59, 753–767 (2000).
   PubMed Web of Science ®Google Scholar
• Bianco R, Yakes FM, Mills GB et al. EGF receptor-overexpressing tumor cells that lack PTEN/MMAC1 and RB are resistant to small molecule EGFR kinase inhibitors. Proc. Am Assoc. Cancer Res. (2001) (Abstract 4567).
   Google Scholar
• Pollack V, Savage D, Baker D et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. JPET291, 739–748 (1999).
   PubMed Web of Science ®Google Scholar
• Iwata K, Miller PE, Barbacci EG et al CP-358,774: a selective EGFR tyrosine kinase inhibitor with potent antiproliferative activity against head and neck tumor cells. Proc. Am. Assoc. Cancer Res. (1997) (Abstract 4248).
   Google Scholar
• Senzer NN, Soulieres D, Siu L et al Phase II evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Pmc. Am. Soc. Clin. Oncol (2001) (Abstract 6).
   Google Scholar
• Perez-Soler R, Chachoua A, Huberman M et al. A Phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy in patients with advanced, EGFR expressing, non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (2001)(Abstract 1235).
   Google Scholar
• Bos M, Mendelsohn J, Kim YM et al PD-153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin. Cancer Res. 3, 2099–2106 (1997).
   Google Scholar
• Nguyen DM, Chen A, Stewart JH et al Sensitization of esophageal cancer cells expressing high levels of epidermal growth factor receptor (EGFR) to chemotherapy (CT) or irradiation (Ir) by the EGFR-specific tyrosine kinase inhibitor PD-153035. Proc. Am Assoc. Cancer Res. (2001) (Abstract 4568).
   Google Scholar
• Fry DW, Bridges AJ, Denny WA et al Specific, irreversible inactivation of the epidermal growth factor receptor and ErbB2, by new class of tyrosine kinase inhibitor. Proc. Nat/Acad. Sri. USA 95, 12022–12027 (1998).
   Google Scholar
• Bruns C, Solorzano C, Harbison M et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 60, 2926–2935 (2000).
   PubMed Web of Science ®Google Scholar
• Lackey K, Affleck K, Allen P et al. The discovery of the new anticancer agent GW2016: a potent dual EGFR/ErbB-2 tyrosine kinase inhibitor. Proc. Am. Assoc. Cancer Res. (2001) (Abstract 4582).
   Google Scholar
• Traxler PM, Furet P, Mett H et al 4-(phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.j Med. Chem. 39, 2285–2292 (1996).
   Google Scholar
• Traxler P, Bold G, Frei J et al Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-di pyrimidines. J. Med. Chem. 40, 3601–3616 (1997).
   Google Scholar
• Grandis JR, Chakraboty A, Zeng Q et al Downmodulation of TGF-a protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J. Cell Biochem. 69, 55–62 (1998).
   PubMed Web of Science ®Google Scholar
• He Y, Zeng Q, Drenning SD et al Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J. Natl Cancer Inst. 90, 1080–1087 (1998).
   Google Scholar
• Fry DW, Nelson JM, McMichael A et al. Specific suppression of the epidermal growth factor receptor tyrosine kinase in tumor cells and ensuing inhibition of clone formation in soft agar. Proc. Am. Assoc. Cancer Res. (1996) (Abstract 2893).
   Google Scholar
• Fry DVV, Nelson JM, Slintak V et al Biochemical and antiproliferative properties of 4-[ar(alk)ylaminolpyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor. Biochem. Pharmacol 54, 877–887 (1997).
   Google Scholar
• Patmore SJ, Roberts BJ, Stoner CL et al. hi viva evaluation of the irreversible EGF receptor tyrosine kinase inhibitor PD 168393. Pmc. Am. Assoc. Cancer Res 560 (1998) (Abstract 39).
   Google Scholar
• Garrison M, Tokher A, McCreery H. A Phase I and pharmacokinetic study of CI-1033, a pan-ErbB tyrosine kinase inhibitor, given orally on day 1, 8 and 15 every 28 days to patients with solid tumors. Pmc. Am. Soc. Clin. Oncol (2001) (Abstract 283).
   Google Scholar
• Shin DM, Nemunaitis J, Zinner RG et al A Phase I clinical and biomarker study of CI-1033, a novel pan-ErbB tyrosine kinase inhibitor in patients with solid tumors. Proc. Am. Soc. Gun. Oncol (2001) (Abstract 324).
   Google Scholar
• Modjahedi H, Affleck K, Stubberfield C et al EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. Int. J. Oncol 13, 335–342 (1998).
   Google Scholar